News
TaraCares agrees MIMOSA™ pilots and launches Menopause Intelligence™ Maturity Index for corporates
TaraCares aims to empower employers to design individualised workplace practices
TaraCares has announced its first MIMOSA™ pilots ahead of launching Menopause Intelligence™ Maturity Index.
TaraCares Global, the developer behind the virtual menopause health literacy and workplace wellbeing platform MIMOSA™, aims to reimagine how female individuals of all ages, ethnicities and genders navigate their unique menopause journey.
A B2B HealthTech SaaS platform, MIMOSA™ is currently available through employers.
Individuals receive user-centric validated research continually personalised to their health profile, real-time history and health trace across 29 health variables extracted from analysing large scale high-quality research on menopause funded by Innovate UK and the National Institute for Health and Care Research (NIHR). This includes physiological and psychological health alongside other life stressors.
MIMOSA™ enables employers to transform from Menopause Friendly to Menopause Intelligent™, helping them benefit from sophisticated signals on the needs and diversity of their menopausal workforce.
This, TaraCares argues, in turn empowers employers to design individualised workplace practices and prevent costs from support built for the average menopause experience.
Already available on Android and iOS in 16 countries, the platform has received positive feedback from clinicians and individual users during the private launch that witnessed a user engagement rate of 84.38 per cent in 11 countries.
In an effort to expand, TaraCares has signed the first pilot for its MIMOSA™ platform with the Hampshire and Isle of Wight (HIOW) Integrated Care Services (ICS) beginning September 2023.
Jyoti Sharma, founder and CEO of TaraCares, said: “We are addressing the menopause health crisis by disrupting the menopause market and the enterprise software employee/people experience economy with MIMOSA™, creating a new category for menopause health literacy and workplace wellbeing.”
Hilary Todd, project director for the Hampshire and Isle of Wight ICS Employee Health and Wellbeing Programme
Hilary Todd, project director for the Hampshire and Isle of Wight ICS Employee Health and Wellbeing Programme, which delivers health and wellbeing support and services to 55,000 NHS and primary care employees, added: “No two experiences of menopause are the same, so we are excited to offer MIMOSA™ to help our people gain personalised insights that support them in understanding and managing their menopause.
“The pilot complements our menopause programme, which is designed to help colleagues feel more confident and ultimately more empowered. We hope that the personalised insights gained make a valuable difference for our people.”
Evidence and feedback
In the US$4.2tn wellness market comprising personalised medicine, healthy eating, nutrition and workplace wellbeing solutions, TaraCares has been unstoppable in integrating its academic and scientific research evidence with tech and clear pathways to value through its collaboration with the Wessex Academic Health Science Network (AHSN) and the York Health Economics Consortium (YHEC).
The research, design and development team behind MIMOSA™
Evidence and feedback is central to TaraCares’s ethos. The company has collaborated with the Academic Health Sciences Networks (AHSN) in England to stay aligned with building for the NHS and has partnered with Gemma Snell, innovation and industry programme manager at NHS Innovation Service.
“Working with Gemma Snell as the innovation lead at the Wessex AHSN has been instrumental in critical analysis to develop MIMOSA™ further; collaborating on the value proposition, arranging market insights opportunities with GPs with special interest in menopause as well as a local NHS ICB Peoples Programme,” said Sharma.
Gemma Snell, innovation and industry programme manager at NHS Innovation Service
Snell, who has spent over 10 years working in the NHS improving clinical pathways and helping health systems to provide the best care and support to patients, added: “I have been pleased to collaborate with Jyoti to realise the potential of MIMOSA™ in supporting women and female individuals to understand and manage their unique menopause so that they can take control and keep living life to the full as they transition through it”
Wessex AHSN’s Insight team also provided expertise around designing evaluation studies, funding opportunities and bid preparations.
Sharma has spent 22 years designing and delivering large-scale people-centric organisational transformations across the Americas, Europe, Middle East and Africa.
She was in her third year of individual differences in menopause research when she decided to found her start-up in May 2022, declining PhD offers from prestigious universities in England and Australia.
“This felt like my life-long PhD,” Sharma explained. “I traded in the Dr title for the translation of our research with tech to deliver improved health for individuals, families, organisations and ultimately our society through this inevitable transition in a female individual’s life.”
After launching the first version of its proprietary Menopause Intelligence™ Maturity Index, Sharma and her team are now focusing on an equity seed investment round that she says will help fuel their rapid growth and expansion into the US and Canada.
MIMOSA™ is available on Android and iOS in India, England, Wales, Scotland, NorthernIreland, Vietnam, Uganda, Nigeria, Kenya, Germany, Switzerland, Austria, Netherlands, USA, UAE, SaudiArabia.
By Women’s Health Week
With four weeks to go until Women’s Health Week USA, the excitement is ramping up!
The final early bird pricing closes this Friday, the full speaker lineup is confirmed, and a record number of pitch applications signals the depth of innovation now moving through the sector as we enter the Era of Scale.
Women’s Health Week USA takes place May 13-14 at the New York Academy of Medicine in New York City, bringing together 600+ senior decision makers spanning investors, founders, multinationals, payers, providers and policymakers around one shared agenda: taking women’s health from growth to scale.
Early bird tickets are available until midnight on Friday, April 17.
Book by then to save up to $600 on your place
The Full Speaker Lineup is Confirmed
The full speaker lineup has finally been confirmed, with 80+ voices spanning investment, innovation, policy, medtech and pharma.
The programme reflects the event’s 2026 theme, The Era of Scale, moving beyond early validation into the harder work of institutionalising women’s health as a category.
Confirmed speakers include Kate Ryder (Maven Clinic), Mallika Mundkur (FDA), Melanie Newman (Planned Parenthood), Nichole Young-Lin (Google), Jill Angelo (OURA), David Stern (Kindbody) and Tammy Sun (Carrot Fertility), alongside representation from the NYSE, ARPA-H, the World Health Organization, Samsung Next, Novo Holdings and more.
170 Pitch Applications and Counting
The Women’s Health Week USA Innovation Showcase received a record 170 applications ahead of its April 10 close, the highest number in the event’s history.
The volume reflects the growing depth of innovation in the sector, but it was the quality of submissions that stood out, with companies across Medical Devices & Therapeutics and Consumer & Tech bringing genuinely differentiated solutions to conditions that have been underserved for decades.
The selected companies will get the chance to pitch on the mainstage at the New York Academy of Medicine in front of the full audience of 600+ investors, corporates, innovators and strategic partners.
Results will be announced next week.
Register your interest to find out who makes the WHW USA Innovator Class of 2026
NYSE Partnership: A Quick Recap
For those who missed our announcement on Femtech World last week, the New York Stock Exchange is the Official Exchange Partner of Women’s Health Week USA 2026.
On the morning of May 13, WHW will feature in the NYSE Market Update, reaching approximately 200 million viewers.
Women’s Health Week will also light up the North Star Billboard in Times Square for a full week around the event, with live and taped interviews distributed across NYSE Live and Taking Stock.
It remains one of the most significant institutional endorsements the women’s health sector has seen.
Early Bird Pricing Closes This Friday
Tickets increase by up to $600 after midnight on Friday, April 17. For anyone with May 13-14 in their calendar, this week is the window to move.
You have until Friday to nominate your femtech company of the year.
The award is one of 10 featuring at Femtech World’s third annual awards event, which attracts entries from across the UK, EU and Europe.
The Company of the Year Award is for companies that have demonstrated exceptional leadership in tackling women’s health needs through groundbreaking products, services or platforms that are shaping the future of global femtech.
If your company is driving innovation, impact and growth in this space, this award was made for you.
About the sponsor: Femovate
The category is backed by Femovate, the global femtech incubator using design to fuel innovation across every stage of a woman’s health journey, from proactive prevention through to personalised treatment.
Femovate has invested over US$2 million in design capital, working side-by-side with founding teams to bring market-ready solutions to life.
The startups it supports have collectively raised US$120 million, launched 30 products, and secured seven FDA clearances.
Why enter?
The Femtech World Awards are free to enter.
Winners and shortlisted companies receive extensive coverage across all Femtech World platforms.
Winners will also receive a trophy and the opportunity to be featured in an interview for the publication.
Find out more about the Femtech World Award and enter here by 4pm BST on Friday 17.
Women with osteoporosis may be more likely to carry a gene linked to Alzheimer’s, according to new research.
Scientists found that APOE4, the most common genetic risk factor for Alzheimer’s, can weaken bone quality in women, even when standard scans appear normal.
The study, carried out by researchers at the Buck Institute for Research on Ageing in California, US, and UC San Francisco, suggests the gene may damage bone at a microscopic level long before any visible signs.
These changes can emerge as early as midlife and remain invisible to routine imaging tests used to assess bone strength.
The findings suggest a link between Alzheimer’s risk and skeletal health and could help pave the way for earlier detection of both conditions.
Professor Birgit Schilling, a senior author of the study, said: “What makes this finding so striking is that bone quality is being compromised at a molecular level that a standard bone scan simply will not catch.
“APOE4 is quietly disrupting the very cells responsible for keeping bone strong – and it is doing this specifically in females, which mirrors what we see with Alzheimer’s disease risk.”
Doctors have long observed that people with Alzheimer’s suffer higher rates of bone fractures, while osteoporosis in women is known to be one of the earliest predictors of the disease.
Now scientists believe they may have uncovered why.
Researchers led by Dr Charles Schurman carried out a detailed analysis of proteins in aged mouse bone and found that tissue was unusually rich in molecules linked to neurological disease, including those associated with Alzheimer’s.
In particular, long-lived bone cells known as osteocytes showed elevated levels of APOE, with levels twice as high in older female mice compared with younger or male animals.
Further experiments using genetically modified mice revealed that APOE4 had a strong and sex-specific impact on both bone and brain tissue.
The disruption at the protein level was even greater in bone than in the brain.
However, the bone structure itself appeared completely normal under scans.
Instead, the gene interfered with a key maintenance process inside bone cells, preventing them from repairing microscopic channels that keep bones strong and resilient.
When this process breaks down, bones become more fragile even if they look healthy on standard imaging.
These results suggest bone cells could potentially act as early biological warning signs of cognitive decline in women carrying APOE4.
Professor Lisa Ellerby, another senior author, said: “We think targeting these cells may open a new front in preserving bone quality in this population.”
Experts say the findings highlight the need to view the body as an interconnected system rather than treating diseases in isolation.
Dementia, of which Alzheimer’s is the most common form, remains one of the UK’s biggest health challenges.
Around 900,000 people are currently living with the condition, a figure expected to rise to 1.6 million by 2040.
It is already the leading cause of death, responsible for more than 74,000 deaths each year.
Events2 weeks agoThree sessions that show exactly where women’s health is heading in 2026
News4 weeks agoLuna and Kindbody partner to bring data-driven insight to women’s health and fertility care
Fertility4 weeks agoMenstruation costs £20,359 a lifetime, sparking calls for Government action
Menopause3 weeks agoCalifornia plans US$3.4m menopause care overhaul
News4 weeks agoHalogen Ventures surpasses 100 investments in female-founded startups
Menopause3 weeks agoWatchdog bans five ads for women’s heath claims
Pregnancy2 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Fertility4 weeks agoPeers push to pardon women criminalised under abortion laws
1 Comment